Imeglimin

Generic Name
Imeglimin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C6H13N5
CAS Number
775351-65-0
Unique Ingredient Identifier
UU226QGU97
Background

Imeglimin has been used in trials studying the treatment of Type 2 Diabetes Mellitus.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus

First Posted Date
2022-05-09
Last Posted Date
2023-11-09
Lead Sponsor
National Center for Global Health and Medicine, Japan
Target Recruit Count
567
Registration Number
NCT05366868
Locations
🇯🇵

Center Hospital of the National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo, Japan

Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
Drug: Imeglimin
First Posted Date
2019-01-14
Last Posted Date
2020-08-11
Lead Sponsor
Poxel SA
Target Recruit Count
14
Registration Number
NCT03802786
Locations
🇩🇪

Apex, Munich, Germany

Bioequivalence of Imeglimin Tablet Formulations

First Posted Date
2018-08-24
Last Posted Date
2019-01-11
Lead Sponsor
Poxel SA
Target Recruit Count
16
Registration Number
NCT03646331
Locations
🇬🇧

Hammersmith Medicines Research (HMR), London, United Kingdom

Effect of Cimetidine on the PK of Imeglimin

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Imeglimin
Drug: Cimetidine
First Posted Date
2018-08-07
Last Posted Date
2018-08-27
Lead Sponsor
Poxel SA
Target Recruit Count
16
Registration Number
NCT03618316
Locations
🇬🇧

Hammersmith Medicines Research (HMR), London, United Kingdom

Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

First Posted Date
2016-10-05
Last Posted Date
2017-02-10
Lead Sponsor
Poxel SA
Target Recruit Count
55
Registration Number
NCT02924337
Locations
🇬🇧

Hammersmith Medicines Research (HMR), London, United Kingdom

Safety, Tolerability and PK of Imeglimin in Japanese Volunteers

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Imeglimin
Drug: Placebo
First Posted Date
2015-02-26
Last Posted Date
2017-02-10
Lead Sponsor
Poxel SA
Target Recruit Count
48
Registration Number
NCT02373150
Locations
🇬🇧

Hammersmith Medicines Research (HMR), London, United Kingdom

A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Imeglimin
Drug: Placebo
First Posted Date
2013-09-26
Last Posted Date
2015-08-13
Lead Sponsor
Poxel SA
Target Recruit Count
315
Registration Number
NCT01951235
Locations
🇱🇻

Pauls Stradins Clinical University Hospital, Riga, Latvia

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy